Experience

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A offering by Accelerate Diagnostics, Inc. of $150 million aggregate principal amount of its 2…

Davis Polk advised Valeant Pharmaceuticals International, Inc. (“Valeant”) in connection with a refinancing transaction pursuant to which its indirect wholly owned subsidiary, Valeant…

Davis Polk advised the joint book-running managers in connection with the $226.3 million public offering of common stock of Xencor, Inc. The common stock is listed on the NASDAQ Global…

Davis Polk advised the joint book-running managers in connection with a $69 million SEC-registered common stock offering by Corvus Pharmaceuticals, Inc. The common stock is listed on the…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with two SEC-registered follow-on offerings of common stock of Atara…

Davis Polk advised the representatives of the several underwriters in an SEC-registered offering of $2.1 billion in aggregate principal amount of Anthem, Inc.’s senior notes, consisting of …

Davis Polk advised the joint book-running managers in connection with a $176 million SEC-registered offering of 5,500,000 shares of common stock of Aimmune Therapeutics, Inc. Aimmune…

Davis Polk advised ViewRay, Inc. in a direct-registered offering of 7,090,581 shares of ViewRay’s common stock and 1,418,116 warrants to purchase shares of ViewRay’s common stock for…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on an SEC-registered offering by Celgene Corporation of $500 million aggregate…

Davis Polk advised the initial purchasers on a Rule 144A offering by Avadel Finance Cayman Limited, a wholly owned subsidiary of Avadel Pharmaceuticals plc, of $143.7 million aggregate…